This site is intended for healthcare professionals

Phase III PEGASUS study of APL 2 shows consistent impact in paroxysmal nocturnal hemoglobinuria.- Apellis Pharma

Read time: 1 mins
Last updated:16th Mar 2021
Published:14th Jun 2020
Condition: Paroxysmal Nocturnal Haemoglobinuria
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest